​

Protagonist Therapeutics (PTGX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PTGX Stock Forecast

Protagonist Therapeutics (PTGX) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $138.40, with a high of $165.00 and a low of $110.00. This represents a -0.17% decline from the last price of $138.64.

- $40 $80 $120 $160 $200 High: $165 Avg: $138.4 Low: $110 Last Closed Price: $138.64

PTGX Stock Rating

Protagonist Therapeutics stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 25 Buy (96.15%), 1 Hold (3.85%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 26 1 25 Strong Sell Sell Hold Buy Strong Buy

PTGX Price Target Upside V Benchmarks

TypeNameUpside
StockProtagonist Therapeutics-0.17%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3413
Avg Price Target$153.67$142.75$114.92
Last Closing Price$138.64$138.64$138.64
Upside/Downside10.84%2.96%-17.11%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26391--13
Jun, 26391--13
May, 26381--12
Apr, 26381--12
Mar, 26381--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 17, 2026Johnson Rice$165.00$132.0224.98%19.01%
Jul 14, 2026Barclays$151.00$129.8916.25%8.92%
Jul 07, 2026Truist Financial$145.00$131.5010.27%4.59%
May 06, 2026Goldman Sachs$110.00$99.2110.88%-20.66%
Apr 14, 2026Srikripa DevarakondaTruist Financial$121.00$103.2117.24%-12.72%
Mar 18, 2026Roger SongJefferies$121.00$97.7823.75%-12.72%
Jan 30, 2026H.C. Wainwright$117.00$79.7346.75%-15.61%
Jan 05, 2026Truist Financial$110.00$87.1826.18%-20.66%
Dec 17, 2025Barclays$108.00$91.5417.98%-22.10%
Oct 28, 2025Srikripa DevarakondaTruist Financial$88.00$76.6814.76%-36.53%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 17, 2026CitigroupOutperformOutperformhold
Jul 14, 2026BarclaysOverweightOverweighthold
Jul 01, 2026Cowen & Co.BuyBuyhold
May 21, 2026Wolfe ResearchOutperforminitialise
May 10, 2026CitigroupBuyBuyhold
May 06, 2026Goldman SachsNeutralNeutralhold
May 06, 2026CitigroupOutperformOutperformhold
Mar 18, 2026JefferiesBuyBuyhold
Mar 18, 2026Johnson RiceBuyBuyhold
Jan 30, 2026H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-3 $-1 $1 $3 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.65$-2.52$-1.39$4.47$-2.05---
Avg Forecast$-2.71$-2.57$-1.62$2.37$-1.30$-1.16$-1.40$0.48
High Forecast$-1.92$-1.61$-1.16$3.24$-0.15$1.99$0.71$0.99
Low Forecast$-4.54$-4.10$-2.09$1.71$-2.27$-2.71$-3.11$0.06
Surprise %-2.21%-1.95%-14.20%88.61%57.69%---

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$27.36M$26.58M$60.00M$434.43M----
Avg Forecast$23.20M$29.85M$60.00M$313.30M$97.97M$135.83M$123.87M$262.81M
High Forecast$35.22M$43.48M$108.70M$376.48M$177.49M$139.83M$224.40M$476.11M
Low Forecast$17.99M$21.25M$19.90M$266.93M$32.50M$131.82M$41.09M$87.17M
Surprise %17.93%-10.95%-38.66%----

Net Income Forecast

$-200M $-100M $0 $100M $200M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-125.55M$-127.39M$-78.95M$275.19M$-130.15M---
Avg Forecast$-122.29M$-137.72M$-78.95M$170.85M$-89.38M$-74.54M$-69.47M$27.36M
High Forecast$-97.83M$-110.18M$-63.16M$183.88M$-8.53M$112.84M$40.54M$56.23M
Low Forecast$-146.75M$-165.27M$-94.75M$97.25M$-128.95M$-153.72M$-176.41M$3.59M
Surprise %2.67%-7.50%-61.07%45.61%---

PTGX Forecast FAQ

Is Protagonist Therapeutics stock a buy?

Protagonist Therapeutics stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 25 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Protagonist Therapeutics is a favorable investment for most analysts.

What is Protagonist Therapeutics's price target?

Protagonist Therapeutics's price target, set by 26 Wall Street analysts, averages $138.4 over the next 12 months. The price target range spans from $110 at the low end to $165 at the high end, suggesting a potential -0.17% change from the previous closing price of $138.64.

How does Protagonist Therapeutics stock forecast compare to its benchmarks?

Protagonist Therapeutics's stock forecast shows a -0.17% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Protagonist Therapeutics over the past three months?

  • July 2026: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 25.00% Strong Buy, 66.67% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Protagonist Therapeutics’s EPS forecast?

Protagonist Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.16, marking a -43.41% decrease from the reported $-2.05 in 2025. Estimates for the following years are $-1.4 in 2027, and $0.48 in 2028.

What is Protagonist Therapeutics’s revenue forecast?

Protagonist Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $135.83M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $123.87M, and $262.81M for 2028.

What is Protagonist Therapeutics’s net income forecast?

Protagonist Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-74.543M, representing a -42.72% decrease from the reported $-130M in 2025. Projections indicate $-69.472M in 2027, and $27.36M in 2028.